LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Home・Aktien・Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals Inc

Geschlossen

1.1 -0.9

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.08

Max

1.11

Schlüsselkennzahlen
By Trading Economics
Einkommen	1.7M -5.1M
Verkäufe	90K 90K
Gewinnspanne	-5,701.111
Angestellte	25
EBITDA	2.6M -4.9M

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+440.54% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	27. März 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-5.6M 36M
Vorheriger Eröffnungskurs	2
Vorheriger Schlusskurs	1.1

Actinium Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

13. Feb. 2026, 16:32 UTC

Ergebnisse

Enbridge, TC Energy Investing in Opportunities to Tap Rising Energy Demand, Boom in Data Centers -- Update

14. Feb. 2026, 22:02 UTC

Ergebnisse

Looking for Dividends? Consider Europe. -- Barrons.com

14. Feb. 2026, 09:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

13. Feb. 2026, 21:57 UTC

Ergebnisse

Stocks Rise on Softer Inflation Data, but AI Jitters Trigger Worst Week Since November -- WSJ

13. Feb. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

13. Feb. 2026, 21:20 UTC

Ergebnisse

Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More Stock Market Movers -- Barrons.com

13. Feb. 2026, 21:05 UTC

Akquisitionen, Fusionen, Übernahmen

Constellation Software: Lumine Group Completes Acquisition of Synchronoss Technologies >CSU.T SNCR

13. Feb. 2026, 20:45 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13. Feb. 2026, 20:45 UTC

Market Talk

Dollar Pares Down Early Losses -- Market Talk

13. Feb. 2026, 20:39 UTC

Market Talk

Potential for Mild Winter Ahead Sinks Natural Gas for Week -- Market Talk

13. Feb. 2026, 20:28 UTC

Market Talk

Oil Settles Week Lower -- Market Talk

13. Feb. 2026, 19:51 UTC

Ergebnisse

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13. Feb. 2026, 19:32 UTC

Market Talk

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13. Feb. 2026, 19:32 UTC

Market Talk

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

13. Feb. 2026, 19:29 UTC

Ergebnisse

Big Tech's Spending Spree Could Limit Buybacks and Dividends -- Barrons.com

13. Feb. 2026, 18:18 UTC

Akquisitionen, Fusionen, Übernahmen

Exxon, Walmart and 9 Other Stocks That Are Soaring Because Cash Is King Again -- Barrons.com

13. Feb. 2026, 17:52 UTC

Ergebnisse

Pinterest's Earnings Give More Proof of Meta Platform's Dominance -- Barrons.com

13. Feb. 2026, 17:16 UTC

Ergebnisse

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

13. Feb. 2026, 17:10 UTC

Akquisitionen, Fusionen, Übernahmen

Vibe-Coding in Gas Town? A Guide to the Software Selloff With 4 Sexy Stock Picks. -- Barrons.com

13. Feb. 2026, 16:59 UTC

Ergebnisse

AppLovin Stock Stabilizes After Selloff. Its Biggest Critic Waves the White Flag. -- Barrons.com

13. Feb. 2026, 16:39 UTC

Akquisitionen, Fusionen, Übernahmen

Berkshire Might Have Sold More Apple, Bank of America Stock in Fourth Quarter -- Barrons.com

13. Feb. 2026, 16:11 UTC

Ergebnisse

Nvidia Stock Wobbles. The Focus Is Turning to Earnings. -- Barrons.com

13. Feb. 2026, 16:07 UTC

Market Talk

Hungarian Forint Could Rise Further -- Market Talk

13. Feb. 2026, 15:54 UTC

Ergebnisse

Detroit Automakers Take $50 Billion Hit as EV Bubble Bursts -- WSJ

13. Feb. 2026, 15:26 UTC

Market Talk

Indian Imports of Saudi Crude Hit Highest Since 2022 -- Market Talk

13. Feb. 2026, 15:01 UTC

Ergebnisse

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Steel Dynamics, Coinbase, DraftKings, Tri Pointe Homes, and More -- Barrons.com

13. Feb. 2026, 15:00 UTC

Ergebnisse

Expedia Falls, but Airbnb Rises. Why Online Travel Stocks Face a Tough Year. -- Barrons.com

13. Feb. 2026, 14:50 UTC

Market Talk

Oil Moves Lower As Market Weighs Geopolitical Risk -- Market Talk

13. Feb. 2026, 14:44 UTC

Ergebnisse

Arista Networks Stock Climbs. Why It Is Outshining Cisco. -- Barrons.com

13. Feb. 2026, 14:22 UTC

Market Talk

Ergebnisse

Global Energy Roundup: Market Talk

Peer-Vergleich

Kursveränderung

Actinium Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

440.54% Vorteil

12-Monats-Prognose

Durchschnitt 6 USD 440.54%

Hoch 9 USD

Tief 4 USD

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Actinium Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

3 ratings

Buy

Halten

Sell

Basierend auf 3 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Actinium Pharmaceuticals Inc – Dist abgegeben haben.

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.